KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Income from Continuing Operations (2019 - 2025)

Historic Income from Continuing Operations for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $355.9 million.

  • Royalty Pharma's Income from Continuing Operations rose 644.89% to $355.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 billion, marking a year-over-year decrease of 49.75%. This contributed to the annual value of $1.3 billion for FY2025, which is 49.75% down from last year.
  • As of Q4 2025, Royalty Pharma's Income from Continuing Operations stood at $355.9 million, which was up 644.89% from $444.2 million recorded in Q3 2025.
  • Royalty Pharma's Income from Continuing Operations' 5-year high stood at $806.8 million during Q2 2021, with a 5-year trough of -$610.0 million in Q4 2022.
  • In the last 5 years, Royalty Pharma's Income from Continuing Operations had a median value of $278.1 million in 2021 and averaged $291.3 million.
  • Per our database at Business Quant, Royalty Pharma's Income from Continuing Operations crashed by 123661.01% in 2022 and then skyrocketed by 1024352.91% in 2025.
  • Quarter analysis of 5 years shows Royalty Pharma's Income from Continuing Operations stood at $53.7 million in 2021, then tumbled by 1236.61% to -$610.0 million in 2022, then surged by 217.63% to $717.6 million in 2023, then plummeted by 53.41% to $334.4 million in 2024, then grew by 6.45% to $355.9 million in 2025.
  • Its Income from Continuing Operations was $355.9 million in Q4 2025, compared to $444.2 million in Q3 2025 and $90.6 million in Q2 2025.